Infliximab: Pharmacological Properties, Mechanism of Action, and Clinical Applications in the Treatment of Selected Inflammatory Diseases
DOI:
https://doi.org/10.12775/QS.2024.36.56477Keywords
Infliximab, TNF-alpha (TNF-α), Inflammatory diseases, Rheumatoid arthritis (RA), Crohn's disease, Psoriasis, Biologic therapy, Monoclonal antibodiesAbstract
Infliximab is a chimeric monoclonal antibody used in the treatment of chronic inflammatory diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. It functions by inhibiting tumor necrosis factor-alpha (TNF-α), a cytokine central to the inflammatory processes of these conditions. Since its approval in 1998, infliximab has significantly improved the management of patients who do not respond well to conventional therapies.
The article provides a comprehensive review of infliximab's pharmacological properties, its mechanism of action, FDA-approved uses, and its clinical benefits. It also discusses its safety profile, which includes potential risks like infections, infusion reactions, and long-term concerns such as an increased risk of malignancies. Regular monitoring of adverse effects is crucial for patient safety during treatment.
Infliximab has demonstrated efficacy in reducing symptoms like pain, swelling, and skin lesions, and it helps in maintaining remission in conditions like Crohn's disease and psoriasis. The drug is typically administered via intravenous infusion, and its dosing varies depending on the disease and patient response. Additionally, the article highlights the role of therapeutic drug monitoring (TDM) to optimize treatment outcomes and reduce healthcare costs.
In conclusion, infliximab remains an essential therapeutic option for managing severe chronic inflammatory diseases, though its use requires careful monitoring due to potential risks. Ongoing research is expected to refine its use and expand its indications, further enhancing its clinical application in inflammatory disease management.
References
Cordoro KM, Feldman SR. TNF-alpha inhibitors in dermatology. Skin Therapy Lett. 2007;12(7):4-6.
Wang J, Zhan Q, Zhang L. A systematic review on the efficacy and safety of Infliximab in patients with psoriasis. Hum Vaccin Immunother. 2016;12(2):431-437. doi:10.1080/21645515.2015.1081322
Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. J Rheumatol. 2004;31(10):1912-1917.
Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443-1453. doi:10.1016/0161-5890(93)90106-l
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [published correction appears in Lancet. 2020 Oct 3;396(10256):e56. doi: 10.1016/S0140-6736(20)32028-6]. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0
Zhao M, Gönczi L, Lakatos PL, Burisch J. The Burden of Inflammatory Bowel Disease in Europe in 2020. J Crohns Colitis. 2021;15(9):1573-1587. doi:10.1093/ecco-jcc/jjab029
Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol. 2017;52(5):535-554. doi:10.1007/s00535-017-1324-3
Ungar B, Levy I, Yavne Y, et al. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2016;14(4):550-557.e2. doi:10.1016/j.cgh.2015.10.025
Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55-62. doi:10.1093/intimm/dxu102
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552-1563. doi:10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W
Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244-279. doi:10.1016/j.pharmthera.2007.10.001
Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol. 2004;13(4):193-222. doi:10.1111/j.0906-6705.2004.00205.x
Wong M, Ziring D, Korin Y, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126(2):121-136. doi:10.1016/j.clim.2007.08.013
Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987;1(8529):355-357. doi:10.1016/s0140-6736(87)91728-4
Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem. 2009;16(24):3152-3167. doi:10.2174/092986709788803024
Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991;285(2):199-212. doi:10.1016/0014-5793(91)80803-b
Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nat Rev Immunol. 2002;2(5):364-371. doi:10.1038/nri802
Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101(5):701-705. doi:10.1111/1523-1747.ep12371679
Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56-63. doi:10.1016/j.cyto.2016.08.014
Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521-1528.
Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111(6):821-831. doi:10.1172/JCI16069
Souto-Carneiro MM, Mahadevan V, Takada K, et al. Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthritis Res Ther. 2009;11(3):R84. doi:10.1186/ar2718
Leipe J, Skapenko A, Lipsky PE, Schulze-Koops H. Regulatory T cells in rheumatoid arthritis. Arthritis Res Ther. 2005;7(3):93. doi:10.1186/ar1718
Bayry J, Lacroix-Desmazes S, Dasgupta S, Kazatchkine MD, Kaveri SV. Efficacy of regulatory T-cell immunotherapy: are inflammatory cytokines key determinants?. Nat Rev Immunol. 2008;8(1):1p-86. doi:10.1038/nri2138-c1
Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002;16(2):111-148.
Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27(5):307-324. doi:10.2165/00002018-200427050-00003
Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf. 2004;27(5):307-324. doi:10.2165/00002018-200427050-00003
Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford). 2007;46(12):1828-1834. doi:10.1093/rheumatology/kem261
Blumenauer B, Judd M, Wells G, et al. Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2002;2002(3):CD003785. doi:10.1002/14651858.CD003785
Gordon M, Sinopoulou V, Akobeng AK, et al. Infliximab for medical induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2023;11(11):CD012623. Published 2023 Nov 20. doi:10.1002/14651858.CD012623.pub2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Julia Słowik, Daniel Zapasek, Mateusz Bajak, Michał Szczepański, Maciej Mamczur, Marcin Kuliga, Julia Inglot, Jadwiga Inglot, Dominik Maciej Feret, Damian Sowa

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 145
Number of citations: 0